Pascale Witz

About Pascale Witz

Independent director of Revvity (RVTY) since 2017, age 58, and currently Founder and President of PWH Advisors (est. 2016). She previously held senior operating roles at Sanofi (Executive Committee; EVP Global Diabetes & Cardiovascular; EVP Global Pharma and Consumer Healthcare) and led GE’s Pharmaceutical Diagnostics business after multiple leadership roles at GE Healthcare; earlier experience at Becton Dickinson Pharmaceutical Systems. Education includes an MBA from INSEAD, an M.S. in biochemistry (INSA Lyon), and doctoral study in molecular biology at CNRS Strasbourg. She is independent under NYSE rules and serves on RVTY’s Audit and Compensation & Benefits Committees.

Past Roles

External Roles

Board Governance

• Independence and roles: Independent director; member, Audit Committee and Compensation & Benefits Committee; designated an “audit committee financial expert.”
• Board structure and leadership: Independent Chair; 9 of 10 directors independent; majority voting in uncontested elections; independent director executive sessions each regular meeting.
• Attendance and engagement: Board met 6 times in FY2024; all directors attended ≥75% of the aggregate Board and committee meetings; all directors attended the 2024 annual meeting.
• Committee activity: Audit (8 meetings in 2024); Compensation & Benefits (5 meetings in 2024).
• Independence determination: Board affirmed independence for Ms. Witz under NYSE 303A.02(b).
• Board service limits: Policy limits directors to ≤3 other public boards (CEO ≤1) absent special approval.

Fixed Compensation

Performance Compensation

• Program design for directors: Non-employee directors receive (1) an annual outright stock award (not subject to vesting) and (2) RSUs vesting at the next annual meeting, subject to continued service (accelerates on death/disability/qualifying retirement or within 12 months post-change-in-control). No performance metrics are applied to director equity.

• 2024 total stock awards reported (Witz): $224,933.

Other Directorships & Interlocks

• Current public boards: Fresenius Medical Care AG; Regulus Therapeutics, Inc.
• Prior public boards: Horizon Therapeutics plc (until 2023); Savencia SA (until 2018); Tesaro, Inc. (until 2019).
• Compensation Committee interlocks: None reported (company discloses no interlocks involving its executives and other entities’ compensation committees).

Expertise & Qualifications

• Financial reporting expertise: Identified as an SEC “audit committee financial expert,” supporting robust oversight of financial reporting and controls.
• Sector/operational depth: ~30 years across life sciences, diagnostics, pharma and medtech, including global P&L leadership and portfolio transformation.
• Education: MBA (INSEAD); M.S. Biochemistry (INSA Lyon); doctoral study in molecular biology (CNRS Strasbourg).
• Independence: Affirmed by RVTY board under NYSE standards.

Equity Ownership

• Unvested RSUs held (Dec 29, 2024): 977.
• Options outstanding (directors): None held by non-employee directors as of Dec 29, 2024.
• Hedging/pledging: Company policy prohibits hedging and pledging of company stock; derivatives and short sales also prohibited.
• Director stock ownership guideline: ≥5x annual cash retainer within 5 years (for 2024, $450,000 threshold); all directors in compliance as of Feb 14, 2025.

Governance Assessment

• Strengths

  • Independent director with deep life sciences operating background and finance literacy; designated audit committee financial expert, enhancing Audit oversight.
  • Active committee roles on Audit and Compensation & Benefits; Board and committees met frequently, and all directors met attendance thresholds, indicating engagement.
  • Strong alignment mechanisms: meaningful equity grants; stock ownership guidelines met; prohibitions on hedging/pledging; no options outstanding reduce risk-taking incentives for directors.
  • Compensation governance: Comp & Benefits Committee uses an independent consultant (Pearl Meyer); no compensation committee interlocks disclosed; broad investor support for pay (95.7% say-on-pay approval in 2024).
  • Independence reaffirmed under NYSE rules.

• RED FLAGS / Watch items

  • Multiple board roles: Currently serves on two other public boards; within RVTY’s policy limit (≤3 other boards), but ongoing monitoring of time commitments is prudent for sustained effectiveness.
  • Related-party exposure: The proxy outlines a formal related-party transaction policy and does not disclose any related-party transactions involving Ms. Witz; continue to monitor given sector overlaps across her external roles.

Director Compensation (2024)

Compensation Committee Analysis

• Committee composition (2024): Peter Barrett (Chair), Michelle McMurry-Heath, Frank Witney, and Pascale Witz; all independent under NYSE rules for compensation committees.
• Consultant and conflicts: Pearl Meyer engaged as independent advisor; committee found no conflicts; consultant does not provide services to management.
• Interlocks: No executive officer interlocks with other entities’ compensation committees reported.
• Meeting cadence: Five meetings in FY2024.

Say-on-Pay & Shareholder Feedback

• 2024 advisory vote on executive compensation: 95.7% of votes cast supported management’s program, indicating strong investor alignment.
• Ongoing investor engagement: Company proactively engages large holders; no requested changes to compensation program noted for 2024.

Related-Party Transactions & Policies

• Policy: Nominating & Corporate Governance Committee reviews/approves related-party transactions; Chair may approve between meetings; annual review for ongoing transactions.
• Disclosure: The proxy includes policy detail and does not disclose any related-party transactions involving Ms. Witz.

Employment & Contracts (Director)

• No employment contract disclosed for non-employee directors; directors paid via board retainer and equity per standard program.

Performance & Track Record (Contextual Signals)

• Board effectiveness context: Independent Chair; executive sessions each regular meeting; active committee oversight of risk (Audit ERM, cybersecurity) and ESG (Nominating & Governance).
• Company pay practices: Clawback policy; no hedging/pledging; no option repricing without shareholder approval; no single-trigger equity vesting for new agreements—supportive of investor confidence.